ImmunoGen, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used for operating activities:
Non-cash royalty revenue related to sale of future royalties
Non-cash interest expense on liability related to sale of future royalties and convertible senior notes
Depreciation and amortization
Gain on sale/disposal of fixed assets and impairment charges
Operating lease right-of-use asset impairment
Stock and deferred share unit compensation
Deferred rent
Change in operating assets and liabilities:
Accounts receivable
Unbilled receivable
Inventory
Contract asset
Prepaid and other current assets
Operating lease right-of-use assets
Other assets
Accounts payable
Accrued compensation
Other accrued liabilities
Deferred revenue
Operating lease liability

Net cash used for operating activities
Cash flows from investing activities:
Proceeds from sale of equipment
Purchases of property and equipment
Net cash used for investing activities
Cash flows from financing activities:
Proceeds from issuance of common stock under stock plans
Proceeds from warrant issuance, net of $391 of transaction costs
Proceeds from common stock issuance, net of $373 and $701 of transaction costs, respectively
Net cash provided by financing activities
Net change in cash and cash equivalents
Cash and cash equivalents, beginning of period
Cash and cash equivalents, end of period
Supplemental cash flow information:
Cash paid during the year for interest

Comments